12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Tactic Pharma, Wilson Therapeutics deal

Wilson acquired Decuprate ( ATN-224) from Tactic. Wilson plans to develop the copper-specific binder for Wilson's disease, a rare autosomal recessive disorder caused by mutation in the ATP7B gene, which leads to an inability to properly...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >